Marshall Edwards, Inc. to Present at the Canaccord Adams 28th Annual Global Growth Conference
August 11 2008 - 8:15AM
Marketwired
Marshall Edwards, Inc. (NASDAQ: MSHL) will present at the Canaccord
Adams 28th Annual Global Growth Conference on Wednesday 13 August,
2008.
About Marshall Edwards, Inc.:
Marshall Edwards, Inc. is a specialist oncology company focused
on the clinical development of novel anti-cancer therapeutics.
Marshall Edwards, Inc. has licensed rights from Novogen Limited
(ASX: NRT) (NASDAQ: NVGN) to bring three oncology drugs --
phenoxodiol, triphendiol and NV-143 -- to market globally. The
Company's lead investigational drug, phenoxodiol, is in a Phase III
multinational multi-centered clinical trial for patients with
recurrent ovarian cancer. More information on the trial can be
found at http://www.OVATUREtrial.com.
Marshall Edwards, Inc. is majority owned by Novogen Limited, an
Australian biotechnology company that is specializing in the
development of therapeutics based on a flavonoid technology
platform. Novogen is developing a range of therapeutics across the
fields of oncology, cardiovascular disease and inflammatory
diseases. More information on phenoxodiol and on the Novogen group
of companies can be found at www.marshalledwardsinc.com and
www.novogen.com.
Under U.S. law, a new drug cannot be marketed until it has been
investigated in clinical trials and approved by the U.S. Food and
Drug Administration ("FDA") as being safe and effective for the
intended use. Statements included in this press release that are
not historical in nature are "forward-looking statements" within
the meaning of the "safe harbor" provisions of the Private
Securities Litigation Reform Act of 1995. You should be aware that
our actual results could differ materially from those contained in
the forward-looking statements, which are based on management's
current expectations and are subject to a number of risks and
uncertainties, including, but not limited to, our failure to
successfully commercialize our product candidates; costs and delays
in the development and/or FDA approval, or the failure to obtain
such approval, of our product candidates; uncertainties in clinical
trial results; our inability to maintain or enter into, and the
risks resulting from our dependence upon, collaboration or
contractual arrangements necessary for the development,
manufacture, commercialization, marketing, sales and distribution
of any products; competitive factors; our inability to protect our
patents or proprietary rights and obtain necessary rights to third
party patents and intellectual property to operate our business;
our inability to operate our business without infringing the
patents and proprietary rights of others; general economic
conditions; the failure of any products to gain market acceptance;
our inability to obtain any additional required financing;
technological changes; government regulation; changes in industry
practice; and one-time events. We do not intend to update any of
these factors or to publicly announce the results of any revisions
to these forward-looking statements.
Contacts: David Sheon 202 422-6999 Email Contact Christopher
Naughton 011 61 2 9878 0088 Email Contact
Kazia Therapeutics (NASDAQ:KZIA)
Historical Stock Chart
From Jun 2024 to Jul 2024
Kazia Therapeutics (NASDAQ:KZIA)
Historical Stock Chart
From Jul 2023 to Jul 2024